A RANDOMIZED, OPEN-LABEL STUDY COMPARING THE BRIA-IMT REGIMEN IN COMBINATION WITH CHECK POINT INHIBITOR VS PHYSICIAN'S CHOICE IN METASTATIC BREAST CANCER

Registry ID

BC-IMT-04

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

BRIACELL THERAPEUTICS CORP.

Start date

2026-07-14

Last update

2025-01-15

Conditions

• BREAST CANCER METASTATIC

Related clinical trials

• HERTHENA-BREAST-01: A PHASE 1B/2, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF PATRITUMAB DERUXTECAN IN PARTICIPANTS WITH HER2 POSITIVE UNRESECTABLE LOCALLY ADVANCED BREAST CANCER OR METASTATIC BREAST CANCER
• A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET) (DYNASTY-BREAST02)
• TUCATINIB, TRASTUZUMAB AND CAPECITABINE WITH BRAIN AND/OR SPINAL RADIOTHERAPY (XRT) IN PATIENTS WITH HER2+, HER2 MUTATED AND/OR HER2- AMPLIFIED METASTATIC BREAST CANCER AND LEPTOMENINGEAL DISEASE: A MULTI-CENTRE PHASE II, SINGLE ARM FEASIBILITY STUDY.
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) (HER2 IHC0 OR HER2-LOW [IHC 1+, IHC 2+/ISH-]) INOPERABLE, LOCALLY ADVANCED, OR METASTATIC BREAST CANCER AND HAVE RECEIVED ENDOCRINE THERAPY
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR THE TREATMENT OF CHEMOTHERAPY-CANDIDATE HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) LOCALLY RECURRENT INOPERABLE OR METASTATIC BREAST CANCER (KEYNOTE-B49)
• AN OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY EVALUATING THE ACTIVITY OF LASOFOXIFENE RELATIVE TO FULVESTRANT FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION

View on source registry